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Summary
Asthma affects three hundred million people worldwide. The effectiveness of
house dust mite allergen control for asthma treatment is debatable. One aspect
that has been little discussed in existing meta‐analyses is the possible role of
environmental strategies. Here, we reintroduce the previously defined strategies
for mite allergen control and discuss their importance to the debate on clinical
effectiveness. The strategy of concurrent bedroom interventions is related to
the combined use of a priori defined interventions, while the strategy of expo-
sure‐based control relates to the treatment of relevant textiles after assessing
exposure. The air purification strategy aims to purify the human breathing zone
of airborne allergens. In Western European patient practice, the use of these
strategies differs. A post hoc study of the dominant Cochrane review by
Gøtzsche and Johansen (Cochrane Database of Systematic Reviews, 2008, Art.
No: CD001187) appears to indicate that a majority of the underlying trials
reported on the strategy of concurrent bedroom interventions, which were
mainly executed in a minimal manner. Some trials have reported on the air
purification strategy and may potentially alter the debate on effectiveness. No
trial has reported on the strategy of exposure‐based control. We therefore
hypothesize that the absence of evidence for the effectiveness of mite allergen
control for asthma treatment applies to the strategy of concurrent bedroom
interventions. The evidence‐based effectiveness of the exposure‐based control
strategy appears to be undetermined. The results of our post hoc reanalysis
urge that future meta‐analyses of mite allergen control should a priori define
the environmental strategy under study. Future trials of mite allergen control
are warranted to test the exposure‐based strategy as well as the sparsely tested
strategy of air purification.
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1 | INTRODUCTION
Asthma affects hundreds of millions of people worldwide, and its
prevalence is still rising.1,2 The role of house dust mite allergy in
asthma is evident; however, it is not exclusive.3 Therapies have been
developed for the treatment of allergic asthma, including avoidance of
mite allergen exposure, immunotherapy and pharmacological treat-
ment.4 However, the effectiveness of mite allergen control has become
debatable,5 and existing guidelines show a lack of consensus on mite
allergen control.6-8 Therefore, gaining knowledge of the clinical effec-
tiveness of avoiding allergen exposure should still be considered a
research priority compared to controlling other types of exposure.9,10
The debate on the effectiveness of mite allergen control for the
treatment of asthma has not been characterized by progress. For
instance, repeated comments have been made on the meta‐analysis by
Gøtzsche et al,5,11,12 pointing to the benefits of multiple trigger ther-
apy in a large trial.13 However, these types of comments have previ-
ously been rejected by Gøtzsche et al,14 who said: “none of the
correspondents have provided data (at the same level of evidence) to
the contrary. Nevertheless, investigators15 continue to mention the
benefits of trials excluded previously by Gøtzsche and Johansen16
One novelty seems to be the introduction of a hypothesis by Tovey
and Ferro that the debate on effectiveness calls for personalized avoid-
ance by a better understanding of the nature of allergen exposure.17
A little‐discussed aspect of the question of clinical effectiveness
is the role of mite allergen control strategies. Strategies have been
defined to avoid house dust mite allergen exposure (see the section
“Strategies for mite allergen control”), including total avoidance,18
exposure‐based control,19 concurrent bedroom interventions,20
purification of the breathing air,21 and a sojourn in a mite‐free
(alpine) environment.22 Environmentally, the reduction in exposure
by different strategies is not necessarily equivalent. It remains
unclear whether the absence of evidence of the clinical effectiveness
of mite allergen control relates to any particular strategy. In this
review, we reintroduce previously defined strategies for mite aller-
gen control and discuss their importance to the debate on clinical
effectiveness, including future investigations.
2 | STRATEGIES FOR MITE ALLERGEN
CONTROL
2.1 | Initial strategies
Among mono‐ and multi‐trigger approaches,23 strategies can be con-
sidered to control exposure to house dust mites and their allergens.
Prior strategies have related to the removal of the patient to a mite‐
free environment. A sojourn in a Swiss alpine mite‐free environment
has been used more than a hundred years and shown to benefit
asthmatic patients temporarily.22 Platts‐Mills et al24 removed
patients for 2 months or more to a dust‐free hospital environment,
resulting in significantly reduced bronchial hyperreactivity. These
prior strategies were continued by the strategy of total avoidance of
the home environment of the asthmatic patients. This strategy of
total avoidance has defined a combination of measures aiming for an
indoor environment completely free of living and dead house dust
mites as well as their faecal products.18,25 The measures developed
have included mainly acaricidal products and mite‐impermeable cov-
ers. However, it became clear that the strategy of total avoidance is
rarely achievable by patients in the long term.26
2.2 | Textile‐based strategies
Meanwhile, strategies were defined to gain the benefits of rigorous
and intensive total avoidance using a more efficient approach. Coll-
off20 defined a set of a priori defined barriers, called integrated avoid-
ance. We redefine this approach as the strategy of concurrent
bedroom interventions: a combined approach aimed at controlling
house dust mite exposure by primarily treating the bedroom environ-
ment with a priori defined barriers. The original strategy comprises a
total of seven barriers. In a more recent publication, Colloff updated
the strategy to nine barriers.27 The five primary barriers consist of (a)
fitting of mite‐impermeable covers to all bedding; (b) monthly hot laun-
dering of the bedding; (c) removal of the bedroom carpet; (d) weekly
vacuuming of other textiles with a high‐efficiency particulate air
(HEPA) filter vacuum cleaner; (e) removal of upholstered furniture,
rugs, mattresses, and bedding to the outside environment for 12 hours
to dry, heat and/or freeze, followed by vacuuming. An alternative is
presented if a primary barrier cannot be executed (four alternatives).
The strategy of concurrent bedroom interventions as positioned by
Colloff20 garnered less attention (three citations, Google Scholar,
retrieved October 21, 2018). This strategy was introduced at the
conference Mites, Asthma and Domestic Design II in Sydney.
Around the same period, van Bronswijk19 introduced the strategy
of selective avoidance. We redefine this strategy as exposure‐based
control: a combined approach based on the assessment of the actual
exposure in the home environment, followed by the extermination
of mites and removal of all relevant sources of allergenic dust. This
strategy assumes the existence of a hygienic threshold for allergen
exposure above which symptoms will develop (2 μg/g dust).25 A sim-
ple colorimetric test was introduced in patient practice that related
the actual exposure in the home environment to the hygienic thresh-
old.28 In the worst case, the exposure‐based strategy results in total
avoidance of the home environment. The strategy of exposure‐based
control gathered only two citations (Google Scholar, retrieved Octo-
ber 22, 2018). We hypothesize that the low number of citations is
due to the publication of this strategy at a conference (International
Conference on Insect Pest in the Urban Environment, Cambridge)
rather than a peer‐reviewed journal.
The measures that constitute the textile‐based strategies can be
differentiated into short‐term and long‐term measures. Short‐term
measures aim to directly reduce allergen exposure, such as the use
of chemical products or washing textiles at 60°C.18 These types of
measures must be repeated throughout the year. Long‐term mea-
sures aim to control allergen exposure only after one or more cli-
matic seasons by lowering the relative humidity in niches during the
heating season (cold climates) or by airing textiles outside during the
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summer (hot climates).27,29 Humidity control is an environmental
intervention aiming to eradicate living mites but not directly the
allergenic mite faeces.19 The mite faeces remain allergenic for a very
long time,30 thus urging humidity control for use in conjunction with
co‐acting environmental methods.27 We judge the sole intervention
of humidity control as a general improvement of indoor air quality
(fresh air) by reducing indoor humidity levels31 but not aiming at the
primary control of mite allergen exposure. In addition to improving
the general quality of the indoor air, long‐term measures are useful
for reducing the need to repeat short‐term measures with high fre-
quency. The reduced need for repeated intensive cleaning of the
home makes mite allergen control more achievable by patients in
the long term.
2.3 | Breathing‐zone‐related strategies
While both the concurrent bedroom interventions strategy and the
exposure‐based strategy focus on the elimination of allergen emis-
sions from textiles, the air purification strategy aims to purify the
human breathing zone of airborne allergens by use of a HEPA filter
capturing at least 85% of particles with a diameter of 0.3 μm.32 Par-
ticles of larger size, such as mite faeces (diameter approximately 10‐
40 μm33), are captured at a higher percentage. HEPA filters can be
used at varying environmental settings, from a laminar airflow in the
breathing zone during sleep34 to the use of portable devices in the
bedroom35 or an air filtration unit in the living room.36
2.4 | Mixed strategies
Finally, we introduce mixed strategies, referring to a combination of
strategies that differ in aim or therapy, such as combining the effec-
tiveness of steroids, immunotherapy, and impermeable covers from
different trials in one meta‐analysis without subgrouping. We con-
sider the mixed strategies somewhat unwieldy. Even if they are clini-
cally effective, the results of mixed strategies are less usable or less
efficient for patient practice, particularly when a strategy is not com-
pletely executed. For instance, patient practice does not combine a
partial impermeable cover with a partial HEPA filter. An exception is
the case when all data from a study result from concurrent and com-
pletely executed strategies. Therefore, insight into the effectiveness of
a single strategy is relevant for evidence‐based clinical decision‐making.
3 | EVIDENCE SUPPORTING THE
STRATEGIES
3.1 | List of meta‐analyses
In the section above, we reintroduced the environmental strategies
for mite allergen control. After the introduction of textile‐based
strategies in the early 1990s, the first meta‐analysis was performed
to assess the effectiveness of mite allergen control at the highest
level of evidence.5 This meta‐analysis was later continued in a
Cochrane review.37 In this meta‐analysis, Gøtzsche and Johansen
included trials on mite‐impermeable covers as well as air purification;
thus, they investigated a mixture of strategies. The next meta‐analy-
sis studied the effectiveness of purifying the air using air filtration
for the treatment of allergic asthma.38 All treatment groups investi-
gated included the use of a HEPA filter, sometimes combined with
mite‐impermeable covers. The HEPA filters were studied in varying
environmental settings. Macdonald et al39 studied the effectiveness
of textile‐based strategies for the primary and tertiary prevention of
asthma. They reported on the number of days ill due to asthma and
a lung function parameter combining the FEV1 with the peak flow.
39
Campbell and Gibson40 attempted to study the effects of feather
bedding, but the selected trials did not meet the inclusion criteria. In
another Cochrane review, Singh and Jaiswal41 studied the effective-
ness of humidity control for the treatment of asthma. We believe
that the environmental strategy studied by Singh and Jaiswal yields
a general improvement of indoor air quality (fresh air) but not mite
control. Crocker et al23 investigated the effectiveness of home‐based
multi‐trigger interventions. The meta‐analysis by Crocker et al23
included a small number of patients with house dust mite allergic
asthma (34%). Three meta‐analyses on the effectiveness of concur-
rent bedroom interventions using mite‐impermeable covers were
introduced in 2014. Arroyave et al42 included seven trials on the
treatment of asthma. In the same year, van Boven43 generated a
hypothesis regarding the effectiveness of mite‐impermeable covers
using a meta‐analysis. Van Boven43 limited the intervention to trials
that covered all bedding elements (mattress, duvet, and pillow), fit-
ting it to the definition of the strategy of concurrent bedroom inter-
ventions.27 Huiyan et al44 investigated six trials on mite‐impermeable
covers combined with one trial on humidity control. Three of the tri-
als investigated by Huiyan et al38-44 were also included in the analy-
sis by Gøtzsche and Johansen.37 To some extent, many meta‐
analyses can be considered to represent subsets of the large meta‐
analysis by Gøtzsche and Johansen.37
3.2 | Clinical effectiveness
Clinical benefits in patients with house dust mite allergy‐related
asthma were reported by small meta‐analyses. McDonald et al38
reported a significant standardized mean difference in the asthma
symptom score (95% CI: −0.69 to −0.25; 88 patients) and the sleep
disturbance (95% CI: −1.44 to −0.42; 47 patients). Macdonald et al39
found a positive reduction in the number of days ill (95% CI: −0.59
to −0.13 by two trials). Van Boven43 observed that the more bed-
room interventions were combined, the higher the reduction in the
mite load from the mattress when the load was high at baseline
(P = 0.02; nine trials). Among the listed meta‐analyses, the meta‐ana-
lysis by Gøtzsche and Johansen37 dominates the debate. While
Gøtzsche and Johansen were unable to demonstrate any clinical
benefit based on 55 trials, Bousquet et al45 concluded from this
meta‐analysis that the use of a single intervention measure is not
effective. Pingitore and Pinter46 mentioned that Gøtzsche and
Johansen included trials reporting no reduction in mite allergen
exposure. As the meta‐analysis by Gøtzsche and Johansen37 reports
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on a mix of strategies without subgrouping, the role of the specific
strategies remains unclear.
4 | THE POSSIBLE ROLES OF STRATEGIES
IN EFFECTIVENESS: AN EXAMPLE
4.1 | Methods
The debate on effectiveness is dominated by the large and rigorous
meta‐analysis by Gøtzsche and Johansen.37 This meta‐analysis on a
mix of strategies did not subgroup for possible differences between
mite allergen control strategies. We post hoc subgrouped the results
by Gøtzsche and Johansen37 into categories based on the environ-
mental strategy used for mite allergen control. The extractions as pub-
lished by Gøtzsche and Johansen37 were the basis of this reanalysis.
Outcomes were limited to the number of patients improved, the
medication usage, the asthma symptom score, the forced expiratory
volume in one‐second (FEV1), and the histamine or methacholine
concentration that caused a 20% reduction in FEV1 (PC20).
The assessment of the type of strategy as studied in the underly-
ing trials yielded three judgements:
• Assessing the strategy used to control mite allergen exposure.
The strategy was defined as “concurrent bedroom interventions”
for any a priori defined intervention aimed at reducing the mite
allergen load while not assessing the relevant sites of exposure in
the home environment.
• If the intervention was judged to follow the strategy of concurrent
bedroom interventions, we assessed the number of barriers used.
• If the strategy of concurrent bedroom interventions was not fol-
lowed consequently, the number of barriers was set at one. For
instance, the single treatment of a carpet in the living room was
judged as one barrier (Barrier 4: Vacuuming of other textiles27).
Effect sizes were calculated by a random‐effects model with the
Metafor package 2.0.047 in R (version 3.4.1).48 Subgroup analysis
yielded a calculation of the effect size related to the environmental
control strategy. We continued subgrouping the strategy of concur-
rent bedroom interventions to the use of one barrier or two or more
barriers. For other statistical aspects, we referred to the original
study by Gøtzsche and Johansen.37 The level of significance was set
to α = 0.05. The magnitude of the standardized mean difference
(SMD) was judged to be small for an SMD of 0.2, medium for an
SMD of 0.5, and large for an SMD of 0.8.49
4.2 | Results of the subgrouping analysis
Gøtzsche and Johansen37 investigated mixed strategies in 55 ran-
domized trials (concurrent bedroom interventions, air purification,
and combinations). Thirty‐six of these trials reported on one or more
outcomes of interest (Table 1; Refs. 34-36,50-82). Thirty trials tested
an intervention based on the strategy of concurrent bedroom inter-
ventions, of which twenty‐three interventions were classified as one
barrier (77%). Seven trials were classified as investigating two or
three barriers (23%). Six trials investigated the air purification strat-
egy. No trial reported on an investigation of the strategy of expo-
sure‐based control. The remaining subgroups that reported on one
barrier (concurrent bedroom interventions) included a total of 3031
patients (74%), the subgroups that reported on two or more barriers
included 817 patients (20%), and the subgroups that reported on air
purification included 258 patients (6%).
The SMD in asthma symptom scores ranged from SMD = −0.03 to
−0.53, with all P‐values ranging from 0.19 to 0.87 (Table 2). Hetero-
geneity ranged from I2 = 54%‐91%. For FEV1, the SMD ranged from
+0.07 to +0.17, with P‐values ranging from 0.08 to 0.81 and negligible
heterogeneity (I2 = 0%‐28%; Table 3). Three subgroups reported on
PC20 outcome, with the SMD ranging from −0.12 to +0.05 (P = 0.45‐
0.80; Table 4). The subgroups showed no heterogeneity (I2 = 0%). For
medication usage, two subgroups reported an SMD = −0.04 to −0.17
(P = 0.46‐0.49; I2 = 0%; Table 5). The risk ratio for the number
improved in the subgroups of concurrent bedroom interventions was
0.85‐1.07 (P = 0.77‐0.87), with an absence of heterogeneity (Table 6).
In the subgroup of air purification, we found a non‐significant risk ratio
of 0.67 (P = 0.61), with an absence of heterogeneity.
4.3 | Discussion of the subgrouping analysis
Overall, post hoc subgrouping shows that the environmental inter-
vention studied in the meta‐analysis by Gøtzsche and Johansen37
relates predominantly to the concurrent bedroom interventions strat-
egy and little to the air purification strategy. A majority of the under-
lying trials reported on the strategy of concurrent bedroom
interventions with one barrier or when performed in an inconsistent
manner that was also classified as one barrier. When grouping the
outcomes of the strategy of concurrent bedroom interventions as
one barrier or two or more barriers, as well as the strategy of air
purification, all effect sizes were not significant. The outcome of the
asthma symptom score showed a non‐significant increase in the
SMD, from zero in the subgroup with one barrier to a small effect in
the subgroup with two barriers, to a larger effect in the group with
air purification. The opposite of this non‐significant increase in the
magnitude of the effect size was a decrease in the number of
patients, which was low in the subgroup with two barriers (n = 246)
and very low in the subgroup with air purification (n = 70). A similar
and smaller tendency was observed in the outcome of medication
usage. The subgroup with one barrier showed zero effect, compared
to a small effect in the subgroup with air purification. However, the
number of patients decreased from 1043 in the subgroup with one
barrier to 72 in the subgroup with air purification. The absence of
significance in air purification may be explained by the small number
of patients studied. However, we cannot exclude the possibility that
the variation in outcomes played a role. These results suggest that
the reintroduction of strategies has the potential to alter the debate
on effectiveness. As our analysis was post hoc, it indicates a need to
include the strategy of mite allergen control as a factor when defin-
ing meta‐analysis protocols.83
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5 | GENERAL DISCUSSION
5.1 | A reintroduction of strategies
This review reintroduces previously defined strategies for mite
allergen control. Both the concurrent bedroom interventions strat-
egy and the exposure‐based strategy were introduced in the early
1990s. These strategies did not attract much attention by research-
ers, possibly because these strategies were not published in peer‐
reviewed journals. Both textile‐based strategies built on the first‐
line reduction or prevention of allergen emissions from textiles are
of primary importance in patient practice. Other defined strategies
include air purification and a sojourn to an (alpine) mite‐free envi-
ronment. The latter two strategies are sparsely studied and not
commonly advised in patient practice, possibly due to their costs.
Only the strategy of removing patients from an environment with
high mite allergen exposure is clearly accepted as effective.14,24
Most of the recent meta‐analyses of textile‐based mite allergen
control for the treatment of asthma do not relate their findings to
a strategy.37,39,40,42,44
TABLE 1 Environmental strategy categories of the trials studied by Gøtzsche and Johansen37
Trial Author Year Strategy Barriers Remark
1 Antoniceli 1991 Air purification NA
2 Bahir 1997 Concurrent bedroom 1
3 Burr 1980A Concurrent bedroom 1
4 Burr 1980B Concurrent bedroom 1
5 Carswell 1996 Concurrent bedroom 3
6 Chang 1996 Concurrent bedroom 1
7 Chen 1996 Concurrent bedroom 1
8 Cinti 1996 Concurrent bedroom 1 Strategy extracted from description
by Gøtzsche and Johansen
9 Cloosterman 1999 Concurrent bedroom 2
10 De_Vries 2007 Concurrent bedroom 1
11 Dharmage 2006 Concurrent bedroom 1
12 Dieteman 1993 Concurrent bedroom 1
13 Dorward 1988 Concurrent bedroom 1
14 Ehnert 1992 Concurrent bedroom 2
15 Fang 2001 Concurrent bedroom 1
16 Geller‐Bernst 1995 Concurrent bedroom 1
17 Halken 2003 Concurrent bedroom 1
18 Htut 2001 Concurrent bedroom 1
19 Huss 1992 Concurrent bedroom 1
20 Kroidl 1998 Concurrent bedroom 1
21 Maesen 1977 Air purification NA
22 Marks 1994 Concurrent bedroom 2
23 Reiser 1990 Concurrent bedroom 1
24 Rijssenbeek 2002 Concurrent bedroom 3
25 Sette 1994 Concurrent bedroom 1
26 Shapiro 1999 Concurrent bedroom 2
27 Sheikh 2002 Concurrent bedroom 1
28 Thiam 1999 Concurrent bedroom 2
29 Van_der_Heide 1997A Concurrent bedroom 1
30 Verrall 1988 Air purification NA
31 Walshaw 1986 Concurrent bedroom 1
32 Warburton 1994 Air purification NA
33 Warner 1993 Air purification NA
34 Woodcock 2003 Concurrent bedroom 1
35 Wright 2009 Concurrent bedroom 1
36 Zwemer 1973 Air purification NA
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5.2 | On textile‐based strategies
A post hoc reanalysis of the dominant meta‐analysis by Gøtzsche
and Johansen37 suggests that a majority of the trials examined had
reported on the use of concurrent bedroom interventions executed
in a minimal manner. The exposure‐based strategy was not tested in
the included trials. This result suggests that it is unknown whether
the conclusion by Gøtzsche and Johansen37 is valid for the expo-
sure‐based strategy. In our opinion, the choice of the strategy of
concurrent bedroom interventions reflects the principals of tradi-
tional clinical trial design.84 In a clinical experiment, the aim is to test
for a possible difference between treatment and no treatment. A
secondary aim in a clinical experiment is to minimize the variance in
outcomes to discriminate a treatment effect in as unbiased a manner
as possible.85 Among the many issues playing a role in minimizing
variance in a trial, we consider the choice of a predefined simple and
homogeneous treatment to be one, for instance, such as the choice
of single bedding covers. However, the opposite of minimizing the
variance is the considerable heterogeneity present in personal expo-
sure. Studies on personal airborne exposure86-88 show that relevant
average exposure is not necessarily related to the sleeping site. Envi-
ronmentally, emission sources, emission magnitudes, emission fre-
quencies, and the presence of patients at emission sites may all vary.
The considerable variance in exposure in patient practice calls for an
exposure‐based strategy. Nonetheless, we do not know of any study
comparing the (clinical) effectiveness of the frequently tested strat-
egy of concurrent bedroom interventions with the exposure‐based
strategy. This research question is relevant, as highly skilled health
practitioners from France and The Netherlands advise their patients
by use of the exposure‐based strategy.89-90
5.3 | Recent studies
Additionally, recent studies have not related their findings to a speci-
fic strategy. Leas et al91 systematically reviewed the effectiveness of
TABLE 2 Standardized mean differences in asthma symptom scores related to environmental strategy in the meta‐analysis by Gøtzsche and
Johansen37
Strategy SMD 95% CI Patients (n) P‐value I2
Sojourn high altitude NA NA NA NA NA
Total avoidance NA NA NA NA NA
Exposure‐based NA NA NA NA NA
Concurrent bedroom −0.07 −0.35 to 0.21 1415 0.62 68%
1 barrier −0.03 −0.37 to 0.32 1169 0.87 54%
2‐3 barriers −0.25 −0.89 to 0.40 246 0.43 91%
Air purification −0.53 −1.35 to 0.30 70 0.19 68%
Mixed strategies −0.13 −0.40 to 0.15 1485 0.35 72%
Gøtzsche & Johansena −0.06 −0.16 to 0.05 1485 0.29 68%
aStandardized mean differences as calculated by Gøtzsche and Johansen37 with a fixed‐effect model.
TABLE 3 Standardized mean differences in FEV1 related to
environmental strategy in the meta‐analysis by Gøtzsche and
Johansen37
Strategy SMD 95% CI
Patients
(n) P‐value I2
Sojourn high
altitude
NA NA NA NA NA
Total avoidance NA NA NA NA NA
Exposure‐based NA NA NA NA NA
Concurrent
bedroom
0.14 −0.02 to 0.29 633 0.08 0%
1 barrier 0.11 −0.11 to 0.33 332 0.32 0%
2‐3 barriers 0.17 −0.06 to 0.40 301 0.15 28%
Air purification 0.07 −0.53 to 0.68 42 0.81 0%
Mixed strategies 0.13 −0.02 to 0.29 675 0.09 0%
Gøtzsche &
Johansena
0.13 −0.02 to 0.28 675 0.09 0%
aStandardized mean differences as calculated by Gøtzsche and Johan-
sen37 with a fixed‐effect model.
TABLE 4 Standardized mean differences in PC20 related to
environmental strategy in the meta‐analysis by Gøtzsche and
Johansen37
Strategy SMD 95% CI
Patients
(n) P‐value I2
Sojourn high
altitude
NA NA NA NA NA
Total avoidance NA NA NA NA NA
Exposure‐based NA NA NA NA NA
Concurrent
bedroom
0.05 −0.09 to 0.20 475 0.45 0%
1 barrier 0.05 −0.20 to 0.30 254 0.68 0%
2‐3 barriers 0.05 −0.21 to 0.32 221 0.69 0%
Air purification −0.12 −1.05 to 0.80 18 0.80 0%
Mixed strategies 0.05 −0.13 to 0.22 493 0.61 0%
Gøtzsche &
Johansena
0.05 −0.13 to 0.22 493 0.61 0%
aStandardized mean differences as calculated by Gøtzsche and Johan-
sen37 with a fixed‐effect model.
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allergen control by subgrouping the control methods but not the
strategies. In the review by Leas et al,91 the assessment of the effect
size remained unclear. Le Cann et al92 reviewed the effectiveness of
home interventions for the treatment of allergy and respiratory dis-
eases. They subgrouped interventions into three categories: educa-
tion‐based methods, physical methods, and a combination of both.
Le Cann et al92 reported mixed results of these home interventions,
urging further study of a multifaceted approach. Murray et al93
investigated the effect of mite‐impermeable covers in a large ran-
domized trial (n = 284) for the treatment of severe asthma exacerba-
tions in children. In this trial, Murray et al93 reported a significant
decrease in the primary outcome of hospitalization, which is sparsely
studied in this field. We classified their intervention as the strategy
of concurrent bedroom interventions using two barriers. From the
observations by Murray et al, we assessed the SMD in asthma symp-
tom score as −0.15 (95% CI: −0.41 to +0.12; P = 0.28), which fitted
satisfyingly to our recalculation for the subgroup with two to three
barriers.
5.4 | Developing the debate?
What does our reintroduction of strategies add to the debate on
allergen control? As stated above, the debate on the effectiveness of
mite allergen control for asthma treatment has not been character-
ized by progress. Our reintroduction of environmental strategies of
mite allergen control continues the call for re‐thinking avoidance.17
This call introduces the idea of improved measurement of personal
exposure,88,94 reflecting the strategy of exposure‐based control.
Exposure‐based control was not the subject of study in any of the tri-
als we analysed post hoc. The post hoc results of the subgroup of air
purification are also of interest and have potential to influence the
debate. For the concurrent bedroom interventions strategy, a ques-
tion arises of the effectiveness of an intervention based on the full
elaboration of this strategy, as this method has not yet been studied.
5.5 | Other domains
Investigations on other allergic disorders caused by mites seem to
show an identical tendency in strategies. Sheikh et al95 conducted a
Cochrane review on the treatment of rhinitis and concluded that
“extensive bedroom‐based environmental control programmes may
be of some benefit” and “evidence that isolated use of house dust
mite impermeable bedding is unlikely to prove effective.” Two trials
stand out in this meta‐analysis. Terreehorst et al96 investigated the
effectiveness of mite‐impermeable covers, classified by us as the
strategy of concurrent bedroom interventions using two barriers.
This large trial (n = 279) did not show clinical benefits for the treat-
ment of rhinitis. A small trial on comprehensive exposure‐based con-
trol showed benefits in the treatment of rhinitis symptom scores and
total IgE.97 In the field of eczema, Kort et al98 showed identical ben-
efits to those found by Kniest et al in a case related to storage mites
by use of the exposure‐based strategy. These results underline the
usefulness of introducing the strategy of mite allergen control in
defining meta‐analysis protocols.
6 | CONCLUSION
In summary, the clinical effectiveness of mite allergen control for the
treatment of asthma is debatable.37 It remains unclear whether the
absence of evidence relates to a specific type of environmental
strategy for mite allergen control, several of which were introduced
in the early 1990s. A post hoc reanalysis suggests that the dominant
conclusions by Gøtzsche and Johansen37 relate to the strategy of
concurrent bedroom interventions, which were mainly executed in a
minimal manner. An evidence‐based effectiveness assessment of the
exposure‐based control strategy, which is used in Western European
patient practice, is still needed. Our post hoc findings indicate that
future meta‐analyses of mite allergen control should a priori define
TABLE 5 Standardized mean differences in medication usage
related to environmental strategy in the meta‐analysis by Gøtzsche
and Johansen37
Strategy SMD 95% CI
Patients
(n) P‐value I2
Sojourn high
altitude
NA NA NA NA NA
Total avoidance NA NA NA NA NA
Exposure‐based NA NA NA NA NA
Concurrent
bedroom
−0.04 −0.16 to 0.08 1043 0.49 0%
1 barrier −0.04 −0.16 to 0.08 1043 0.49 0%
2‐3 barriers NA NA NA NA NA
Air purification −0.17 −0.64 to 0.29 72 0.46 0%
Mixed strategies −0.05 −0.17 to 0.07 1115 0.39 0%
Gøtzsche &
Johansena
−0.05 −0.17 to 0.07 1115 0.39 0%
aStandardized mean differences as calculated by Gøtzsche and Johan-
sen37 with a fixed‐effect model.
TABLE 6 Risk ratios for the number of patients improved related
to environmental strategy in the meta‐analysis by Gøtzsche and
Johansen37
Strategy RR 95% CI Patients (n) P‐value I2
Sojourn high altitude NA NA NA NA NA
Total avoidance NA NA NA NA NA
Exposure‐based NA NA NA NA NA
Concurrent bedroom 1.06 0.75‐1.50 282 0.82 0%
1 barrier 1.07 0.75‐1.53 233 0.77 0%
2‐3 barriers 0.85 0.19‐3.79 49 0.87 0%
Air purification 0.67 0.24‐1.87 56 0.61 0%
Mixed strategies 1.01 0.73‐1.40 338 0.96 0%
Gøtzsche & Johansena 1.01 0.80‐1.27 338 0.94 0%
aRisk ratios as calculated by Gøtzsche and Johansen37 with a fixed‐effect
model.
406 | VAN BOVEN ET AL.
the environmental strategy under study. Future trials of mite allergen
control are warranted to test the exposure‐based strategy as well as
the sparsely tested strategy of air purification.
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